The Fly | CELZ

Proprietary Technology Platform: Creative Medical Technology Holdings, Inc. develops and utilizes unique, patented, or patent-pending technologies, particularly in the realm of regenerative medicine and stem cell therapies, providing a distinct foundation for its product development.

Diverse Therapeutic Pipeline: The company pursues a broad range of indications across multiple therapeutic areas, such as neurology, urology, and orthopedics, diversifying its market potential and reducing dependence on a single product's success.

Strong Intellectual Property Portfolio: A robust collection of patents and intellectual property rights protects its novel discoveries, treatment methods, and product candidates, creating barriers to entry for competitors.

Clinical Trial Failure Risk: The company's product candidates may not achieve positive results in clinical trials, delaying or preventing regulatory approval and commercialization.

Regulatory Approval Risk: Failure to obtain necessary regulatory approvals from the FDA or international agencies could prevent the company from marketing its product candidates.

Capital Needs and Dilution Risk: The company will require significant additional financing to continue operations and develop its product candidates, which may result in substantial dilution for existing shareholders.

Clinical Trial Failure Risk: The company's product candidates may not achieve positive results in clinical trials, delaying or preventing regulatory approval and commercialization.

Regulatory Approval Risk: Failure to obtain necessary regulatory approvals from the FDA or international agencies could prevent the company from marketing its product candidates.